Analysis of ApoE and SLCO1B1 genetic polymorphisms of patients with Han nationality in Hebei region of China

doi:10.3969/j.issn.1672-6731.2021.05.012

Abstract

Abstract:

Objective To analyze the distribution of ApoE and SLCO1B1 genetic polymorphisms of patients with cardiovascular and cerebrovascular diseases in Han nationality of Hebei region. Methods Patients with cardiovascular and cerebrovascular diseases admitted to our hospital corresponding department from June 2019 to October 2020 were selected. The polymorphisms of ApoE and SLCO1B1 genes in 4193 patients with cardiovascular and cerebrovascular diseases were detected qualitatively by polymerase chain reaction (PCR)-fluorescence probe technique, to analyze the distribution characteristics of polymorphism and compare the genotype distribution difference between male and female. Results The observed mutation frequencies of ApoE and SLCO1B1 gene polymorphism of Han nationality in Hebei region were consistent with the Hardy-Weinberg genetic balance. Moreover, there was no significant difference in the distribution of ApoE gene polymorphism at 388T > C and 526C > T and SLCO1B1 gene polymorphism at 388A > G and 521T > C between men and women (P > 0.05). Among the six genotypes of ApoE in Han nationality people, genotype ε3/ε3 accounted for 68.57% (2875/4193), followed by ε3/ε4 (15.48%, 649/4193), ε2/ε3 (12.81%, 537/4193), ε2/ε4 (1.69%, 71/4193), ε4/ε4 (0.98%, 41/4193), and ε2/ε2 (0.48%, 20/4193). There was no significant difference in the distribution of ApoE gene phenotypes between male and female (P=0.223). Among the seven genotypes of SLCO1B1 gene, *1b/*1b and *1a/*1b accounted for the largest proportion 39.57% (1659/4193) and 31.05% (1302/4193), while other genotypes *1b/*15, *1a/*1a, *1a/*15, *15/*15 and *1a/*5 accounted for 14.31% (600/4193), 7.20% (302/4193), 6.42% (269/4193), 1.43% (60/4193) and 0.02% (1/4193) respectively. There was no significant difference in the distribution of SLCO1B1 gene phenotypes between male and female (P=0.078). Conclusions The distribution of ApoE and SLCO1B1 gene polymorphisms is different in patients with cardiovascular and cerebrovascular diseases in Han nationality of Hebei region, and the distribution of ApoE and SLCO1B1 genetic polymorphisms is independent of gender.

Key words: Cerebrovascular disorders, Cardiovascular diseases, Apolipoprotein E4, Solute carrier organic anion transporter family member 1b1, Genes, Han nationality, Hebei

摘要：

目的分析河北地区汉族人群中心脑血管病患者ApoE和SLCO1B1基因多态性分布情况。方法以2018年6月至2019年10月于河北医科大学第一医院神经内科和心内科就诊的4193例心脑血管病患者为研究对象，利用聚合酶链反应（PCR）-荧光探针技术定性检测其外周全血基因组中ApoE和SLCO1B1基因多态性分布情况，分析基因多态性分布特点，比较不同性别之间基因型分布差异。结果 4193例河北地区汉族心脑血管病患者的ApoE以及SLCO1B1基因多态性位点突变频率观察值符合Hardy-Weinberg遗传平衡；男女之间ApoE基因单核苷酸多态性位点388T > C、526C > T，以及SLCO1B1基因单核苷酸多态性位点388A > G、521T > C分布差异无统计学意义（P > 0.05）。在ApoE基因的6种表型中，ε3/ε3所占比例最大，为68.57%（2875/4193）；其他表型ε3/ε4、ε2/ε3、ε2/ε4、ε4/ε4、ε2/ε2占比依次为15.48%（649/4193）、12.81%（537/4193）、1.69%（71/4193）、0.98%（41/4193）和0.48%（20/4193）；不同性别之间ApoE基因表型分布差异无统计学意义（P=0.223）。SLCO1B1基因的7种表型中，*1b/*1b、*1a/*1b的占比较大，分别为39.57%（1659/4193）和31.05%（1302/4193），其他表型*1b/*15、*1a/*1a、*1a/*15、*15/*15、*1a/*5占比依次为14.31%（600/4193）、7.20%（302/4193）、6.42%（269/4193）、1.43%（60/4193）和0.02%（1/4193）；不同性别之间SLCO1B1基因表型分布差异无统计学意义（P=0.078）。结论河北地区汉族人群中心脑血管病患者ApoE和SLCO1B1基因多态性分布不均匀，且ApoE和SLCO1B1基因多态性分布与性别无关。

关键词: 脑血管障碍, 心血管疾病, 载脂蛋白E4, 溶质运载体有机阴离子转运家族成员1b1, 基因, 汉族, 河北

HE Sha, GOU Dong-yun, WANG Wen-yuan, LIU Zi-qian, YANG Jie, WANG Yan-yong, SUN Jing-na, ZHANG Ling-yi, MA Xiao-wei. Analysis of ApoE and SLCO1B1 genetic polymorphisms of patients with Han nationality in Hebei region of China[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2021, 21(5): 400-405.

何莎, 苟东芸, 王文远, 刘紫倩, 杨洁, 王彦永, 孙静娜, 张令怡, 马晓伟. 河北地区汉族心脑血管病患者ApoE和SLCO1B1基因多态性分析[J]. 中国现代神经疾病杂志, 2021, 21(5): 400-405.

/ / Recommend / Download Citations

URL: https://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2021.05.012

https://journal11.magtechjournal.com/cjcnn/EN/Y2021/V21/I5/400

References

[1] Hisham NF, Bayraktutan U. Epidemiology, pathophysiology, and treatment of hypertension in ischaemic stroke patients[J]. J Stroke Cerebrovasc Dis, 2013, 22:e4-14.
[2] Bevan S, Traylor M, Adib-Samii P, Malik R, Paul NL, Jackson C, Farrall M, Rothwell PM, Sudlow C, Dichgans M, Markus HS. Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations[J]. Stroke, 2012, 43:3161-3167.
[3] Das S, Kaul S, Jyothy A, Munshi A. Association of APOE (E2, E3 and E4) gene variants and lipid levels in ischemic stroke, its subtypes and hemorrhagic stroke in a South Indian population[J]. Neurosci Lett, 2016, 628:136-141.
[4] Wei LK, Au A, Menon S, Griffiths LR, Kooi CW, Irene L, Zhao J, Lee C, Alekseevna AM, Hassan MRA, Aziz ZA. Polymorphisms of MTHFR, eNOS, ACE, AGT, ApoE, PON1, PDE4D, and ischemic stroke:meta-analysis[J]. J Stroke Cerebrovasc Dis, 2017, 26:2482-2493.
[5] Kumar A, Kumar P, Prasad M, Misra S, Kishor Pandit A, Chakravarty K. Association between apolipoprotein epsilon4 gene polymorphism and risk of ischemic stroke:a meta-analysis[J]. Ann Neurosci, 2016, 23:113-121.
[6] Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins[J]. Lancet, 2005, 366:1267-1278.
[7] Zintzaras E, Kitsios GD, Triposkiadis F, Lau J, Raman G. APOE gene polymorphisms and response to statin therapy[J]. Pharmacogenomics J, 2009, 9:248-257.
[8] Zeng HS, Wang DW. Guidelines for the Diagnosis and Treatment of Internal Cardiovascular Diseases[M]. 3rd. Beijing:Ke Xue Chu Ban She, 2013:75-116.[曾和松, 汪道文. 心血管内科疾病诊疗指南[M]. 3版. 北京:科学出版社, 2013:75-116.]
[9] Chinese Society of Neurology, Chinese Stroke Society. Diagnostic criteria of cerebrovascular diseases in China (version 2019)[J]. Zhonghua Shen Jing Ke Za Zhi, 2019, 52:710-715.[中国各类主要脑血管病诊断要点2019[J]. 中华神经科杂志, 2019, 52:710-715.]
[10] Zhang JX, Zhang ZY, Liu B, Zhang R, Zhang HW, Zhang CF, Wang YN. The relation between apolipoprotein E gene polymorphism and ischemic stroke in Chinese Han population:a Meta analysis[J]. Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi, 2017, 15:1700-1703.[张晋霞, 张志勇, 刘斌, 张蕊, 张宏伟, 张彩凤, 王雅楠. 汉族人群载脂蛋白E基因多态性与缺血性脑卒中相关性的Meta分析[J]. 中西医结合心脑血管病杂志, 2017, 15:1700-1703.]
[11] Chinese Joint Committee on The Revision of Guidelines for the Prevention and Treatment of Dyslipidemia in Adults. Chinese guidelines for prevention and treatment of dyslipidemia in adults (2016 revision)[J]. Zhongguo Xun Huan Za Zhi, 2016, 31:937-950.[中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 31:937-950.]
[12] Cano-Corres R, Candás-Estébanez B, Padró-Miquel A, Fanlo-Maresma M, Pintó X, Alía-Ramos P. Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia[J]. J Clin Lab Anal, 2018, 32:e22566.
[13] Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R; SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy:a genomewide study[J]. N Engl J Med, 2008, 359:789-799.
[14] Romaine SP, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1(OATP1B1) gene polymorphisms on response to statin therapy[J]. Pharmacogenomics J, 2010, 10:1-11.
[15] Zhang MD, Gu W, Qiao SB, Zhu EJ, Zhao QM, Lv SZ. Apolipoprotein E gene polymorphism and risk for coronary heart disease in the Chinese population:a meta-analysis of 61 studies including 6634 cases and 6393 controls[J]. PLoS One, 2014, 9:e95463.
[16] Song Y, Stampfer MJ, Liu S. Meta-analysis:apolipoprotein E genotypes and risk for coronary heart disease[J]. Ann Intern Med, 2004, 141:137-147.
[17] Jin ZQ, Fan YS, Ding J, Chen M, Fan W, Zhang GJ, Zhang BH, Yu SJ, Zhang YS, Ji WF, Zhang JG. Association of apolipoprotein E 4 polymorphism with cerebral infarction in Chinese Han population[J]. Acta Pharmacol Sin, 2004, 25:352-356.
[18] Wang QY, Wang WJ, Wu L, Liu L, Han LZ. Meta-analysis of APOE ε2/ε3/ε4 polymorphism and cerebral infarction[J]. J Neural Transm (Vienna), 2013, 120:1479-1489.
[19] Tang H, Yan X, Hua Y, Wei M, Zhang L, Gao J, Dong H. Distribution of apoE polymorphism in Chinese Yunnan Dehong Dai ethnic group[J]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 2005, 22:224-226.
[20] Zhong Z, Wu H, Li B, Li C, Liu Z, Yang M, Zhang Q, Zhong W, Zhao P. Analysis of SLCO1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China[J]. J Clin Lab Anal, 2018, 32:e22408.
[21] Wang JW, Li Y, Qiao B, Chen JJ. An analysis on the polymorphisms of SLCO1B1 and APOE in central China and its clinical significance[J]. Shi Yong Yi Xue Za Zhi, 2018, 34:3041-3046.[王京伟, 李艳, 乔斌, 陈娟娟. 华中地区汉族人群SLCO1B1与APOE基因多态性分析及临床意义[J]. 实用医学杂志, 2018, 34:3041-3046.]
[22] Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1[J]. Pharmacogenomics, 2008, 9:19-33.
[23] Xiang Q, Zhang X, Ma L, Hu K, Zhang Z, Mu G, Xie Q, Chen S, Cui Y. The association between the SLCO1B1, apolipoprotein E, and CYP2C9 genes and lipid response to fluvastatin:a meta-analysis[J]. Pharmacogenet Genomics, 2018, 28:261-267.
[24] Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1:a genetically polymorphic transporter of major importance for hepatic drug uptake[J]. Pharmacol Rev, 2011, 63:157-181.
[25] Danik JS, Chasman DI, MacFadyen JG, Nyberg F, Barratt BJ, Ridker PM. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy[J]. Am Heart J, 2013, 165:1008-1014.
[26] Liu JE, Liu XY, Chen S, Zhang Y, Cai LY, Yang M, Lai WH, Ren B, Zhong SL. SLCO1B1521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients:a nested case-control study[J]. Eur J Clin Pharmacol, 2017, 73:1409-1416.
[27] Luo BC, Zhang J. Correction analysis between ApoE/Slco1B1 genetic polymorphism and ischemic stroke[J]. Zu Zhong Yu Shen Jing Ji Bing, 2018, 25:264-266.[罗宝昌, 张敬. ApoE和Slco1B1基因多态性与缺血性脑卒中的相关性分析[J]. 卒中与神经疾病, 2018, 25:264-266.]

Please choose a citation manager

Content to export